Key Takeaways & Executive Findings
- •• DILI pathogenesis involves oxidative stress, mitochondrial dysfunction, and immune-mediated pathways, offering multiple targets for pharmacological intervention. • Emerging therapies, including antioxidants and anti-inflammatory agents, show promise in mitigating liver injury and improving clinical outcomes. • Accurate prediction and diagnosis of DILI remain challenging, highlighting the need for reliable biomarkers and advanced in vitro models. • A multidisciplinary approach integrating clinical, pharmacological, and toxicological expertise is essential for effective management of DILI.
Abstract
Drug-induced liver injury (DILI) remains a significant clinical challenge, with a wide spectrum of presentations ranging from asymptomatic transaminase elevations to acute liver failure. This comprehensive review synthesizes current knowledge on the pharmacological modulation of DILI, focusing on the underlying mechanisms, risk factors, and emerging therapeutic strategies. We discuss the role of oxidative stress, mitochondrial dysfunction, and immune-mediated pathways in the pathogenesis of DILI. Furthermore, we highlight the potential of novel pharmacological agents, including antioxidants, anti-inflammatory compounds, and hepatocyte growth factors, in mitigating liver injury. The review also addresses the challenges in predicting and diagnosing DILI, emphasizing the need for biomarkers and advanced in vitro models. Our findings underscore the importance of a multidisciplinary approach in managing DILI and pave the way for future research aimed at improving patient outcomes.
1. Introduction
Drug-induced liver injury (DILI) is a leading cause of acute liver failure and a major reason for drug withdrawal from the market. The liver's central role in drug metabolism makes it particularly susceptible to toxic insults, and the clinical presentation of DILI can vary widely, from mild biochemical abnormalities to severe hepatic necrosis. Despite significant advances in understanding the mechanisms of DILI, its unpredictable nature and the lack of effective therapies continue to pose substantial challenges in clinical practice and drug development.
This review aims to provide a comprehensive overview of the pharmacological modulation of DILI, focusing on the molecular pathways involved and the potential therapeutic strategies that are currently being explored. We will discuss the role of oxidative stress, mitochondrial dysfunction, and immune-mediated responses in the pathogenesis of DILI, as well as the emerging role of biomarkers and in vitro models in improving diagnosis and prediction. By synthesizing the latest research, we hope to offer insights that can guide future investigations and clinical management of this complex condition.
Loading authentic research manuscript (Pages 1–5)...
John A. Smith, Emily R. Johnson, Michael T. Brown, Sarah L. Davis (2026). Pharmacological Modulation of Drug-Induced Liver Injury: A Comprehensive Review. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is drug-induced liver injury (DILI)?
Drug-induced liver injury (DILI) is an adverse reaction to medications or other substances that causes liver damage, ranging from mild enzyme elevations to acute liver failure. It is a significant cause of drug withdrawal and clinical concern.
What are the main mechanisms of DILI?
The main mechanisms include oxidative stress, mitochondrial dysfunction, and immune-mediated pathways. These processes lead to hepatocyte injury, inflammation, and apoptosis.
How is DILI diagnosed?
Diagnosis is based on clinical history, liver function tests, exclusion of other causes, and sometimes liver biopsy. Biomarkers are being developed to improve accuracy and early detection.
What are the emerging treatments for DILI?
Emerging treatments include antioxidants (e.g., N-acetylcysteine), anti-inflammatory agents, and hepatocyte growth factors. These aim to mitigate liver injury and promote regeneration.
Why is DILI a challenge in drug development?
DILI is unpredictable, often not detected in preclinical trials, and can be severe. This leads to late-stage drug failures and post-marketing withdrawals, emphasizing the need for better predictive models and biomarkers.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.